. 2023 Mar 9;13:1054072. doi: 10.3389/fonc.2023.1054072

Table 3.

Response outcomes - Subgroup analysis.

Outcomes	Interventions in the control group	Studies	Participants	Heterogeneity test results		Effect model	Meta-analysis results
Outcomes	Interventions in the control group	Studies	Participants	P	I²	Effect model	95%CI	P
PR	LEN+PD-1	2	240	0.24	28%	Fixed	1.53 [1.07, 2.20]	0.02
PR	LEN+TACE	2	223	0.36	0%	1.93 [1.22, 3.05]	0.005
SD	LEN+PD-1	2	240	0.05	33%	Fixed	0.88 [0.62, 1.27]	0.50
SD	LEN+TACE	2	223	0.09	35%	1.21 [0.72, 2.03]	0.47
ORR	LEN+PD-1	2	240	0.62	0%	Fixed	0.20 [0.08, 0.32]	0.001
ORR	LEN+TACE	2	223	0.25	25%	0.13 [-0.02, 0.28]	0.08
DCR	LEN+PD-1	2	227	0.36	0%	Fixed	4.61 [2.27, 9.37]	0.0001
DCR	LEN+TACE	2	223	0.60	0%	1.90 [1.05, 3.44]	0.03

PR, partial remission; SD, stable disease; ORR, Overall response rate; DCR, Disease control rate; TACE, transcatheter arterial chemoembolization; PD-1, programmeddeath-1; LEN, Lenvatinib.